Red Door secures MabThera UK job

Roche has turned to Red Door Communications to promote its anti-cancer product MabThera across all its indications in the UK.

The move comes ahead of an important year for MabThera, with Roche seeking to extend its use. A NICE Single Technology Appraisal of MabThera is also taking place this year.

Red Door has promoted the product's use for treating rheumatoid arthritis since last year but has now bagged a PR/med-ed contract spanning MabThera's entire repertoire.

It won the brief in a four-way pitch (PRWeek, 11 November 2005).
Ketchum previously promoted MabThera in the non-Hodgkin's lymphoma area. The agency continues to promote the brand internationally.

Roche is seeking European approval for the product to treat what is known as indolent lymphoma.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in